MeiraGTx Holdings plc ( NASDAQ:MGTX ) is possibly approaching a major achievement in its business, so we would like ...

MeiraGTx has struck a deal with Hologen Limited, an artificial intelligence (AI) company specialising in multimodal ...

Joint venture, Hologen Neuro AI, will expedite Phase 3 development of AAV-GAD for Parkinson’s Disease and industrialize ...

With MeiraGTx eyeing up how to take the drug through phase 3 and onto commercialization, Hologen has stepped in. The ...

MeiraGTx and Hologen form a neuro-AI drug development joint venture, with up to $430M in funding to advance Parkinson's and CNS treatments.

Today announced strategic collaboration with Hologen AI, including a $200 million upfront payment to MeiraGTx and the formation of a joint ...

MeiraGTx (MGTX) stock gains as the company teams up with Hologen to form a JV to advance gene therapies for Parkinson's and other CNS diseases. Read more here.

RBC Capital raised the firm’s price target on MeiraGTx (MGTX) to $13 from $11 and keeps an Outperform rating on the shares after its Q4 ...

MeiraGTx has one gene therapy in a potentially pivotal clinical trial for cancer patients and another gene therapy ready to start Phase 3 in Parkinson’s disease. Completing the studies will be ...

MeiraGTx (NASDAQ:MGTX – Get Free Report) will likely be releasing its earnings data before the market opens on Thursday, March 13th. Analysts expect MeiraGTx to post earnings of ($0.48) per share and ...

MeiraGTx Holdings shares rose 13% in premarket trading on a collaboration with Hologen that will bring in a cash infusion and create a joint venture. Shares were trading around $7.28. The stock is up ...